Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial (CLUE).
Robert TerkeltaubJisoo LeeJiyoung MinSeonghye ShinKenneth G SaagPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Tigulixostat significantly lowered sUA levels compared to placebo at all doses used with an acceptable safety profile.